De novo donor-specific antibody (dnDSA) is associated with antibody-mediated rejection (AMR) and allograft loss, yet the allograft histology associated with dnDSA remains unclear. The aim of this study was to examine the allograft histology associated with dnDSA in patients with serial surveillance biopsies. We retrospectively studied adult conventional solitary kidney transplant recipients from October 2007 to May 2014. The definition of dnDSA was new donor-specific antibody (DSA) with mean fluorescence intensity (MFI) >1000. The incidence of dnDSA was 7.0% (54 of 771) over mean follow-up of 4.2 AE 1.9 years. Patients with dnDSA had reduced death-censored allograft survival (87.0% vs. 97.0% no dnDSA, p < 0.01). Moreover, 94% of patients received a biopsy after dnDSA (mean of three biopsies per patient). AMR was present in 25.0% and 52.9% of patients at dnDSA detection and at 1 year, respectively. Patients with both class I and II dnDSA had the highest rate of allograft loss. The higher the sum MFI at dnDSA detection, the higher the incidence of AMR.
In conclusion, patients with dnDSA without AMR at time of detection may benefit from a follow-up biopsy within 1 year because AMR can be missed initially. In addition, the dnDSA class and sum MFI at baseline appear to be prognostic. The higher the sum MFI of dnDSA at baseline, the higher the incidence of AMR.
Introduction
De novo donor-specific antibody (dnDSA) is a major risk factor for chronic antibody-mediated rejection (AMR) and allograft loss (1) (2) (3) (4) (5) . The reported incidence of dnDSA varies from 6.2% to 27.8% depending on the cohort studied (2) (3) (4) (6) (7) (8) (9) , and up to 24% of allografts fail within 3 years of dnDSA detection (3) . Medication nonadherence and previous acute cellular rejection in the setting of class II HLA mismatch are the main risk factors for dnDSA development (2, 3, 6 ), yet a subset of transplant recipients develop early dnDSA for reasons that are unclear. Regardless, no available therapy has been proven effective, emphasizing the need for prevention and therapeutic clinical trials.
The problem is that designing a clinical trial to prevent or treat patients with dnDSA is difficult. The number of patients who develop dnDSA is relatively small. Not all patients with dnDSA develop AMR or graft loss, and many patients have stable allograft function for years (6) . Including these patients in a clinical trial is not ideal because they would receive unnecessary treatment, which would dilute any treatment effect, thus necessitating a larger trial. Enriching a study population with patients who are the most likely to progress to a meaningful clinical end point is a critical component in the design of an effective clinical trial.
Our goal was to examine serial allograft biopsies in patients with dnDSA to identify a subgroup of patients most likely to progress to allograft failure. We also aimed to identify potentially modifiable risk factors for dnDSA outside of medication nonadherence, acute cellular rejection, and HLA mismatch. We studied a predominantly white living donor kidney transplant population that underwent surveillance donor-specific antibody (DSA) testing and allograft biopsy.
Materials and Methods
This study was approved by the Mayo Clinic institutional review board. We performed a retrospective cohort study of the risk factors and outcomes of our adult solitary conventional kidney transplant recipients who were transplanted between October 2007 and May 2014. We studied only the initial transplant from patients who were retransplanted at our center during the studied time period (n = 5), and we excluded patients if no baseline single antigen bead (SAB) results were available (n = 8), if DSA was not tested after transplant (n = 25), or if the patient had a positive crossmatch and/or DSA was detected with mean fluorescence intensity (MFI) >1000 at the time of transplant (n = 158). Data was collected by chart review. Patients were censored at last follow-up.
Assessment of dnDSA
A SAB solid-phase assay (LABScreen; One Lambda, Canoga Park, CA) was used to identify alloantibody specificities at baseline and after transplant. The definition of dnDSA was any DSA identified after transplant that reached MFI >1000 that was not detected at any time prior to transplant (each patient had at least one SAB test prior to transplant). Our center protocol is to obtain SABs at least yearly when patients are on the kidney transplant waiting list, immediately before transplant, 4 mo after transplant, and yearly after transplant thereafter. SABs are also routinely performed at the time of allograft dysfunction or acute cellular rejection.
Assessment of medication adherence
This information was obtained from the clinical record. We defined medical nonadherence as documented missing labs, unexplained low immunosuppressive drug levels, missed appointments, medications not refilled, or patients who were admittedly nonadherent.
Biopsy assessment
Surveillance biopsies were done at 4, 12, 24, and 60 mo after transplant as standard of care. Biopsies were also performed for allograft dysfunction, proteinuria, or based on provider discretion (i.e. known dnDSA). Kidney biopsy tissue was processed for light microscopy and C4d by immunofluorescence (Bio-Rad Antibodies [formerly AbD Serotec], Raleigh, NC), if indicated.
Light microscopy features of biopsies were scored by slightly modified Banff criteria (10) (11) (12) . Specifically; acute active AMR was diagnosed in patients with dnDSA if three features were present according to Banff 2013 guidelines: (i) histologic evidence of acute tissue injury including glomerulitis (g >0) and/or peritubular capillaritis (ptc >0), intimal or transmural arteritis (v >0), thrombotic microangiopathy, or acute tubular injury, in the absence of any other apparent cause; (ii) evidence of current or recent antibody interaction with vascular endothelium including C4d ≥2 with immunofluorescence on frozen section and/or g + ptc ≥2; and (iii) serologic evidence of DSAs.
The presence of transplant glomerulopathy (cg >0) signified chronic AMR. In this study, patients with acute, active AMR could have cg >0, which is a modification from the Banff 2013 guidelines; therefore, some patients met criteria for acute, active AMR and chronic AMR simultaneously. Electron microscopy was not routinely done in all cases, and it was not used to determine the presence of chronic AMR.
Immunosuppression and treatment protocols
Patients received anti-thymocyte globulin (ATG; Thymoglobulin; Sangstadt, Menlo Park, CA), 1.5 mg/kg per day for four doses; anti-CD25 receptor antibodies (Simulect, Novartis Pharmaceuticals, East Hanover, NJ); or alemtuzumab (Campath; Genzyme, Cambridge, MA) as induction per center protocol. Currently, alemtuzumab is the standard induction agent if the patient age is <65 years, the B cell flow cytometric crossmatch is negative, and no DSA is detected with MFI >2000; anti-CD25 receptor antibodies are given if the patient is ≥65 years with a negative crossmatch; and ATG is given to all other patients. Prior to 2011, alemtuzumab was not part of routine protocol. At that time, ATG was given to all patients unless they were aged ≥65 years and had a negative B cell flow cytometric crossmatch, in which case they received anti-CD25 receptor antibodies.
Standard maintenance immunosuppression consisted of prednisone, tacrolimus, and mycophenolate mofetil in patients who receive induction with ATG and anti-CD25 antibodies. Patients were on a steroid-free immunosuppression protocol if they received alemtuzumab induction (tacrolimus and mycophenolate mofetil only).
Because no therapy has been proven effective for the sustained reduction in DSA, no specific therapy for dnDSA was given outside of routine treatment for acute cellular rejection, mixed acute cellular rejection and AMR, or low immunosuppressive levels. Specifically, 75.9% (42 of 54) patients received no new therapy during follow-up; 11.1% (6 of 54) received thymoglobulin, intravenous immunoglobulin (IVIG), and plasmapheresis for mixed acute cellular rejection and AMR; 9.3% (5 of 54) received corticosteroids for acute cellular rejection alone; and 1.9% (1 of 54) received IVIG therapy alone.
Laboratory monitoring
All patients had their serum creatinine and estimated GFR (eGFR) assessed at least every 3 mo. At yearly intervals, patients had more thorough assessment of their renal function that included iothalamate clearance testing and 24-h urine protein testing.
Statistical analysis
Statistical analysis was performed on JMP v10 (SAS Institute, Cary, NC). For numerical data, groups were compared with the t-test or the Wilcoxon rank sum test, as indicated. Counts and percentages were compared using the Fisher exact test. Odds ratios (ORs) were used and described by their point estimate and corresponding 95% confidence intervals (CIs). Logistic regression was used for multivariate analysis to determine the risk factors for dnDSA. Time-to-event data were summarized for each group using Kaplan-Meier estimates. Cox regression with a time-dependent variable (dnDSA) was used to test between groups (Wald test at the 0.05 level). Testing was two-sided at the 0.05 level. The paired t-test was used to compare paired continuous data, and the McNemar test was used to compare paired proportions. Figure 1 shows a flow chart of the patients in the study. Baseline characteristics are shown in Table 1 . Overall mean follow-up was 4.2 + 1.9 years and was similar among those developing dnDSA and those in whom dnDSA was never detected. The incidence of dnDSA was 7.0% during this time frame. In our cohort, the transplant recipients were predominantly white, and 82.3% (637 of 771) received their transplant from a living donor. There was no difference in sex, race, donor type, cause of end-stage renal disease, calculated panel reactive antibody, prior organ transplant, or prior polyomavirus among patients who did or did not develop dnDSA. Patients who developed dnDSA were younger (mean age 48.3 AE 15.6 vs. 53.0 AE 13.8 years, p = 0.04) and had more HLA mismatches (mean 4.2 AE 1.5 vs. 3.6 AE 1.9, p < 0.01). The majority of patients received thymoglobulin for induction immunosuppression, but there was a higher proportion of patients who received alemtuzumab in the dnDSA cohort than the non-dnDSA cohort (31.5% [ Characteristics of dnDSA Overall, 7% of patients developed dnDSA. The mean time to dnDSA detection after transplant was 1.8 AE 1.6 years ( Figure 2) , and 3.2% (25 of 771) of patients developed dnDSA within 1 year after transplant. Anticlass I DSA alone was present in 9.3% (5 of 54), anticlass II DSA alone was present in 70.4% (38 of 54), and anti-class I and II DSA was present in 20.4% (11 of 54) of patients (Table 3 ). In total, 29.6% (16 of 54) had anticlass I dnDSA and 90.7% (49 of 54) had anti-class II dnDSA. The dnDSA completely disappeared during follow-up in 16.7% (9 of 54) of patients. The distribution of dnDSA MFI is shown in Table 3 .
Results

Demographics
Allograft survival
Patient and overall allograft survival were similar among patients who did or did not develop dnDSA, as shown in Figure 3 ; however, patients with dnDSA had reduced death-censored allograft survival (p = 0.01). Actuarial death-censored allograft survival was 87.0% in patients who developed dnDSA and 97.0% in patients who did not develop dnDSA (p = 0.01). The mean time to death-censored allograft failure after dnDSA detection was 1.6 AE 1.7 years.
Progression of clinical and subclinical AMR
In total, 160 biopsies were obtained from 94.4% (51 of 54) of the studied patients at the time of dnDSA detection or afterward (mean of three biopsies per patient). Biopsies were obtained at the time of dnDSA detection in 74.1% (40 of 54) of patients. At 1 year after dnDSA detection, biopsies were obtained in 68.0% (34 of 50) of the surviving patients with a functioning allograft. Overall, 65.2% (30 of 46) of the surviving allografts had biopsies ≥2 years after dnDSA detection. Acute, active AMR was present in 33.3% (10 of 30) and chronic AMR was present in 16.7% (5 of 30) of those remaining allografts. Only three patients (10% of patients who received a biopsy >1 year after dnDSA detection) had newly detected acute, active AMR that was not present at baseline or 1 year after dnDSA detection.
The individual Banff scores at the time of and at 1 year after dnDSA detection are presented in Figure 5 . Prior to de novo donor-specific antibody formation. 
Allograft function
At the time of dnDSA detection, the mean iothalamate clearance was 55.0 AE 20.4 mL/min per body surface area (BSA), and at 1 year after detection, it decreased to 52.5 AE 18.6 mL/min per BSA (p < 0.01, paired t-test) (Figure 6 ). At the end of follow-up (a mean of 3.2 AE 2.0 years following dnDSA detection), the mean iothalamate GFR (Figure 7 ).
The incidence of graft failure and the composite end point was similar among patients with only class I, only class II, and no dnDSA detected during follow-up ( Figure 7 ). In contrast, incidence of both end points was higher in patients with both class I and II dnDSA detected. Graft failure and the composite end point occurred in 54.6% (6 of 11) of patients with both class I and II dnDSA (p < 0.01 compared with no dnDSA) ( Figure 7 ).
In contrast, the incidence of acute, active AMR and chronic AMR was higher in patients with dnDSA regardless of the class of dnDSA present ( Figure 7) . The incidence of acute, active AMR was 60.0% (3 of 5), 52.8% (19 of 36), and 70.0% (7 of 10) in patients with class I, class I, and classes I and II dnDSA, respectively (p < 0.01 for all classes). Chronic AMR was detected in 60.0% (3 of 5), 30.6% (11 of 36), and 50.0% (5 of 10) of patients with only class I, only class II, and both class I and II dnDSA, respectively (p < 0.01 for all classes).
No patients lost their allograft during follow-up if their dnDSA completely disappeared. The rates of the composite end point; acute, active AMR; and chronic AMR were similar in patients with transient dnDSA compared with patients without dnDSA (Figure 8 ).
There were numeric trends toward increased allograft failure and the composite end point in patients with a higher total sum MFI at baseline, but this did not reach statistical significance (p = 0.09 and p = 0.44, respectively; Cochran test for trend). Patients with a total MFI 3000-6000 and >6000 had higher rates of acute, active AMR compared with patients with total MFI >3000 at baseline (p = 0.03, Cochran test for trend). Specifically the rate of acute, active AMR was 39.3% (11 of 28) in patients with MFI <3000 at baseline, 75.0% (8 of 11) in patients with MFI 3000-6000 at baseline, and 72.7% (8 of 11) with MFI >6000 at baseline. The rate of chronic AMR was similar in patients regardless of baseline total dnDSA MFI ( Figure 8 ).
Of all patients with dnDSA, only those with histologic evidence of acute, active AMR either at DSA detection or on subsequent biopsy had an increased incidence of graft failure and/or 50% reduction in eGFR ( Figure 9 ). Overall, 21.4% (6 of 28) of the allografts failed in patients with dnDSA and AMR, whereas none failed in patients with dnDSA and no AMR (p < 0.01 for dnDSA plus AMR vs. no dnDSA; p = 1.0 for dnDSA without AMR vs. no dnDSA). The incidence of graft failure and/or 50% reduction in eGFR occurred in 35.7% (10 of 28) of patients with dnDSA and AMR, 17.3% (4 of 23) of those with dnDSA and no AMR, and 9.6% (69 of 717) of patients with no dnDSA (p < 0.01 for dnDSA plus AMR vs. no dnDSA; p = 0.26 for dnDSA without AMR vs. no dnDSA).
Discussion
The presence of dnDSA is associated with AMR and allograft loss, but most patients actually have a functioning allograft for the first few years after dnDSA detection. In this study, patients with both anti-class I and II dnDSA had the highest rate of graft loss and the composite end point of graft loss and/or 50% reduction in eGFR. More than half of this small subgroup of patients had allograft failure within 3.2 years following dnDSA detection. We also found that, regardless of the class of dnDSA present, only those patients who developed AMR (i.e. microvascular inflammation) had allograft failure or the composite end point of allograft failure or 50% eGFR, even when the vast majority of the AMR episodes in our cohort were subclinical. No patients in the dnDSA group without AMR had allograft loss.
The use of protocol biopsy allowed us to better understand the progression to AMR after dnDSA. When dnDSA was detected, only 25.0% had histologic findings of acute, active AMR, but the incidence increased to 52.9% by 1 year after dnDSA detection. Consequently, patients without histologic evidence of AMR at the time of dnDSA detection may benefit from a follow-up biopsy within 1 year after dnDSA detection because AMR may be missed on the initial biopsy. Finding new AMR on biopsies performed >1 year after dnDSA detection was unusual, which suggests that some patients with dnDSA never develop AMR. This deserves further study.
Although the SAB output is semiquantitative, the sum MFI of dnDSA at baseline has some prognostic value: The higher the sum MFI at baseline, the higher the incidence of acute, active AMR. In addition, patients whose dnDSA completely disappeared during follow-up had similar rates of graft failure; the composite end point of graft failure and Cochran test for trend comparison outcomes in patients with dnDSA MFI <3000, 3000-6000, and >6000 at baseline. AMR, antibody-mediated rejection; dnDSA, de novo donor-specific antibody; eGFR, estimated GFR; MFI, mean fluorescence intensity. 50% decline in eGFR; acute, active, AMR; and chronic AMR as those without dnDSA. Moreover, dnDSA completely disappeared in only a small number of patients-a phenomenon that also deserves further study.
Other studies on this subject have also reported detailed histologic findings following dnDSA, but most biopsies were obtained at the time of dnDSA detection (2) or for allograft dysfunction (3, 9) . The incidence of AMR at the time of dnDSA detection was lower than that reported in other cohorts (6, 9) , but that was likely because biopsies performed in our cohort were mainly performed for surveillance and not for allograft dysfunction. Our results are particularly informative because we studied biopsies at more than one time point (mean of three biopsies per patient). We also confirmed many previously reported findings. Like de Kort et al, we found that the presence of microvascular inflammation (acute, active AMR in our cohort) was associated with allograft failure (9). The overall incidence of dnDSA in our cohort was also consistent with that previously reported (2,3,6,13), and we found that DQ mismatch, prior medication nonadherence, and acute cellular rejection were linked to the development of dnDSA (2, 3, 6) .
The main limitation of our study was the relatively short follow-up. We reported the most comprehensive histologic follow-up after dnDSA, but the same patients did not have biopsies at all time points, which limited our ability to truly describe the evolution and timing of light microscopic findings. We also did not assess the impact of epitope mismatches on dnDSA development (14) or the effect of DSA characteristics such as titer, IgG subclasses, or C1q (15,16) on prognosis. Finally, we used a 50% reduction in eGFR as a clinical outcome, although it is not currently approved by the U.S. Food and Drug Administration for clinical trials in transplantation (17) (18) (19) .
These data reemphasize the importance of developing effective therapy either to prevent dnDSA formation or to treat its consequences; however, designing a clinical trial to study this is difficult. We believe a prevention trial is unreasonable, given the relatively low incidence of dnDSA. As others have already discussed (6), a multicenter effort with thousands of patients would be required to adequately power a study, and many patients would be treated unnecessarily. Even a treatment trial in patients with identified dnDSA would require a prolonged multicenter effort. The best approach may be to enroll dnDSA patients with acute, active AMR into a treatment trial because this is a large subset of patients at the greatest risk of graft failure. This approach would minimize the number of patients treated unnecessarily and † All statistical comparisons were to the no dnDSA group. AMR, antibody-mediated rejection; dnDSA, de novo donor-specific antibody; eGFR, estimated GFR. maximize the potential to detect a meaningful effect from a potential therapeutic agent.
In conclusion, the development of dnDSA is associated with a progressive increase in antibody-mediated injury in more than half of patients within 1 year of detection. The patients who ultimately developed AMR were at high risk of graft failure and/or 50% reduction in GFR. Nevertheless, there are potentially modifiable risk factors including ensuring medication adherence and avoiding HLA mismatch, especially at the DQ locus.
